Cancer Society American .2022 .. Accessed, : .
Cancer Society American .2022 .Key statistics for lung cancer. Accessed, : .
Comprehensive Cancer Network National .2023 .Clinical practice guidelines in oncology. , : .
Lawler S.E. . .Oncolytic viruses in cancer treatment: a review. ” JAMA Oncology, 2(2016) : 841-849.
Russell S.J. . .Oncolytic virotherapy. Nature Biotechnology, 30(2012) : 658-670.
Balasubramanian A. .2025 .Effects of CVA21, an oncolytic virus, in combination with pembrolizumab on immunogenicity and the tumor microenvironment in advanced NSCLC: a phase I/II trial. Clinical Cancer Research, 25(22) : 1078-0432.
Song D. . .Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. ” Signal Transduction and Targeted Therapy, 7(2022) : 100.
Garcia-Carbonero R. . .Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. ” Journal for ImmunoTherapy of Cancer, 5(2017) : 71.
Bradbury P.A. .2018 .Canadian Cancer Trials Group (CCTG) IND211: a randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic nonsmall cell lung cancer receiving standard salvage therapy. ” Lung Cancer, 03 : 142-148.
Hu L. .2015 .Oncolytic Newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. American Journal of Cancer Research, 5(12) : 3612-3623.
Patel M.R. .2019 .JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. ” Cancer Gene Therapy, 26 : 411-418.
Guan J. .2023 .A phase 2 study of in situ oncolytic virus therapy and stereotactic body radiation therapy followed by pembrolizumab in metastatic non-small cell lung cancer. International Journal of Radiation Oncology, 08(2024) : 1531-1540.
Ribas A. .2017 .Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell, 08(2017) : 1109-1119.
Annels N.E. .2019 .Phase I trial of an ICAM-1-targeted immunotherapeutic Coxsackievirus A21 (CVA21) as an oncolytic agent against non-muscle-invasive bladder cancer. ” Clinical Cancer Research, 18(19) : 1078-0432.
Mahalingam D. .2018 .A phase II study of pelareorep (REOLYSIN®) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. ” Cancers, 10 : 160.
Khuri F.R. . .A controlled trial of intratumoral ONYX015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine, 6(2000) : 879-885.
Sakamoto A. . .Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer. Scientific Reports, 13(2023) : 5924.
Cui B. . .Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNAdamage response inhibitors. ” Signal Transduction and Targeted Therapy, 8(2023) : 366.
Lawler S.E. .2064 .Oncolytic viruses in cancer treatment: a review. ” JAMA Oncology, 3(2017) : 841-849.
Lord C.J.,Ashworth A. .2017 .PARP inhibitors: synthetic lethality in the clinic. ” Science, 355(6330) : 1152-1158.
Slamon D.J. .2001 .Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. ” The New England Journal of Medicine, 344(11) : 783-792.
Mok T.S. .2009 .Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. ” The New England Journal of Medicine, 361(10) : 947-957.
Rosenfeld M.R. .2010 .A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. ” Neuro-Oncology, 12(10) : 1071-1077.
Andtbacka R.H. .2014 .Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. ” Journal of Clinical Oncology, 58(25) : 2780-2788.